11:42 AM EDT, 07/02/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Wednesday the US Food and Drug Administration has granted accelerated approval for Lynozyfic, a treatment for adults with hard-to-treat multiple myeloma.

The decision is based on early results from a clinical trial showing a 70% response rate, including 45% of patients who saw their cancer treated, the company said.

Shares of the company were up more than 2% in recent trading.

Price: 549.23, Change: +14.32, Percent Change: +2.68